← All candidates
250 insider filings on record.
250 filings on record.
MDGLMADRIGAL PHARMACEUTICALS, INC.
NasdaqGS · Healthcare · $12.22B
$529.09
+1.11% · Sep 16
250 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 176 sells◆ 1 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what MDGL ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$12.22B
Float
13.7M
59% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
55.0
Price / sales
9.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Baker Bros. Advisors LP
Bought $9.96M on Aug 18 — 26,704 sh @ $372.87, held indirect, 1.4% of their stake.
5 of 5 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
245 more transactions on Pro →Context
Wall St
$678.71 avg target
+28.3% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$1.38 act+$2.76
Q4 '25−$2.57 act−$1.69
Q3 '25−$4.96 act−$2.96
Q2 '25−$1.90 act+$1.63
Coverage
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales GrowthSimply Wall St. · 05-10Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpZacks · 05-07Madrigal Pharmaceuticals Q1 Earnings Call HighlightsMarketBeat · 05-06Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
The file stays open
250 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice